Erratum: Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia (The Pharmacogenomics Journal (2016) 16 (530-535) DOI: 10.1038/tpj.2015.63);Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia

Pharmacogenomics Journal

Volumn 16, Issue 6, 2016, Pages 530-535

  Krajinovic, M ^a,b   Elbared, J ^a   Drouin, S ^a   Bertout, L ^a   Rezgui, A ^a   Ansari, M ^a,c   Raboisson, M J ^a   Lipshultz, S E ^d   Silverman, L B ^e   Sallan, S E ^e   Neuberg, D S ^f   Kutok, J L ^e   Laverdire, C ^a,b   Sinnett, D ^a,b   Andelfinger, G ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN 5; RAZOXANE; ABCC5 PROTEIN, HUMAN; ANTINEOPLASTIC ANTIBIOTIC; CARDIOTONIC AGENT; MULTIDRUG RESISTANCE PROTEIN; NOS3 PROTEIN, HUMAN;

ABCC5 GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; CARDIOTOXICITY; CHILDHOOD CANCER SURVIVOR; CHILDHOOD LEUKEMIA; ECHOCARDIOGRAPHY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HEART EJECTION FRACTION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; NOS3 GENE; PRIORITY JOURNAL; ADOLESCENT; ADULT; CHEMICALLY INDUCED; CHILD; CONTROLLED STUDY; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HEART CONTRACTION; HEART DISEASES; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; HETEROZYGOTE; HOMOZYGOTE; INFANT; METABOLISM; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; PHENOTYPE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; PROTECTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBIOTICS, ANTINEOPLASTIC; CARDIOTONIC AGENTS; CARDIOTOXICITY; CHILD; CHILD, PRESCHOOL; DEXRAZOXANE; DOXORUBICIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEART DISEASES; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INFANT; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYOCARDIAL CONTRACTION; NITRIC OXIDE SYNTHASE TYPE III; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTECTIVE FACTORS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84941236436     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.86     Document Type: Erratum

References (48)

1. Kremer LC, Caron HN. Anthracycline cardiotoxicity in children. N Engl J Med 2004; 351: 120-121.
2. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Inter Med 1996; 125: 47-58.
3. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23: 2629-2636.
4. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart 2008; 94: 525-533.
5. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K. Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention-review of the literature. Med Sci Monit 2000; 6: 411-420.
6. Mushlin PS, Cusack BJ, Boucek Jr. R.J., Andrejuk T, Li X, Olson RD. Time-related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function. Br J Pharmacol 1993; 110: 975-982.
7. Thorn CF, Oshiro C, Marsh S, Hernandez-Boussard T, McLeod H, Klein TE et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011; 21: 440-446.
8. Wojnowski L, Kulle B, Schirmer M, Schluter G, Schmidt A, Rosenberger A et al. NAD (P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity. Circulation 2005; 112: 3754-3762.
9. Semsei AF, Erdelyi DJ, Ungvari I, Csagoly E, Hegyi MZ, Kiszel PS et al. ABCC1 polymorphisms in anthracycline-induced cardiotoxicity in childhood acute lymphoblastic leukaemia. Cell Biol Int 2012; 36: 79-86.
10. Armenian SH, Ding Y, Mills G, Sun C, Venkataraman K, Wong FL et al. Genetic susceptibility to anthracycline-related congestive heart failure in survivors of haematopoietic cell transplantation. Br J Haematol 2013; 163: 205-213.
11. Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM, Relling MV et al. Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related congestive heart failure after childhood cancer. Cancer 2008; 112: 2789-2795.
12. Rajic V, Aplenc R, Debeljak M, Prestor VV, Karas-Kuzelicki N, Mlinaric-Rascan I et al. Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood. Leuk Lymphoma 2009; 50: 1693-1698.
13. Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dube MP, Al-Saloos H et al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J Clin Oncol 2012; 30: 1422-1428.
14. Wang X, Liu W, Sun CL, Armenian SH, Hakonarson H, Hageman L et al. Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. J Clin Oncol 2014; 32: 647-653.
15. Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS et al. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-Treated survivors of childhood high-risk leukemia. Cancer 2013; 119: 3555-3562.
16. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
17. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL et al. Postinduction dexamethasone and individualized dosing of Escherichia coli L-Asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31: 1202-1210.
18. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L et al. Longterm results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 320-334.
19. Rousseau J, Gagne V, Labuda M, Beaubois C, Sinnett D, Laverdiere C et al. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. Blood 2011; 118: 5883-5890.
20. Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagne V, Rousseau J et al. Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia. Clin Cancer Res 2014; 21: 329-334.
21. Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL et al. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-Treated children with high-risk acute lymphoblastic leukaemia: long-Term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol 2010; 11: 950-961.
22. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-367.
23. Ansari M, Sauty G, Labuda M, Gagne V, Laverdiere C, Moghrabi A et al. Polymorphisms in multidrug resistance-Associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. Blood 2009; 114: 1383-1386.
24. Ansari M, Sauty G, Labuda M, Gagne V, Rousseau J, Moghrabi A et al. Polymorphism in multidrug resistance-Associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia. Pharmacogenomics J 2012; 12: 386-394.
25. Krajinovic M, Labuda D, Mathonnet G, Labuda M, Moghrabi A, Champagne J et al. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. Clin Cancer Res 2002; 8: 802-810.
26. Marcoux S, Robaey P, Gahier A, Labuda M, Rousseau J, Sinnett D et al. Role of NOS3 DNA variants in externalizing behavioral problems observed in childhood leukemia survivors. J Pediatric Hematol Oncol 2013; 35: e157-e162.
27. Storey JD, Taylor JE, Siegmund D. Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach. J R Stat Soc B (Stat Methodol) 2004; 66: 187-205.
28. Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR et al. The effect of dexrazoxane on myocardial injury in doxorubicin-Treated children with acute lymphoblastic leukemia. N Engl J Med 2004; 351: 145-153.
29. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP, Moss J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 2000; 97: 2832-2835.
30. Polanski AK, Ebner A, Ebner B, Hofmann A, Steinbronn N, Brandt A et al. Dexrazoxane prevents the development of the impaired cardiac phenotype in caveolin-1-disrupted mice. J Cardiovasc Pharmacol 2013; 61: 545-552.
31. Neilan TG, Blake SL, Ichinose F, Raher MJ, Buys ES, Jassal DS et al. Disruption of nitric oxide synthase 3 protects against the cardiac injury, dysfunction, and mortality induced by doxorubicin. Circulation 2007; 116: 506-514.
32. Deng S, Kruger A, Schmidt A, Metzger A, Yan T, Godtel-Armbrust U et al. Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice. Naunyn Schmiedebergs Arch Pharmacol 2009; 380: 25-34.
33. Mungrue IN, Husain M, Stewart DJ. The role of NOS in heart failure: lessons from murine genetic models. Heart Fail Rev 2002; 7: 407-422.
34. Brunner F, Andrew P, Wolkart G, Zechner R, Mayer B. Myocardial contractile function and heart rate in mice with myocyte-specific overexpression of endothelial nitric oxide synthase. Circulation 2001; 104: 3097-3102.
35. Chand S, Chue CD, Edwards NC, Hodson J, Simmonds MJ, Hamilton A et al. Endothelial nitric oxide synthase single nucleotide polymorphism and left ventricular function in early chronic kidney disease. PLoS One 2015; 10: e0116160.
36. Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC et al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr Blood Cancer 2013; 60: 1375-1381.
37. Lal S, Mahajan A, Chen WN, Chowbay B. Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. Curr Drug Metab 2010; 11: 115-128.
38. Yoshida M, Suzuki T, Komiya T, Hatashita E, Nishio K, Kazuhiko N et al. Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin. Int J Cancer 2001; 94: 432-437.
39. Luo JQ, Wen JG, Zhou HH, Chen XP, Zhang W. Endothelial nitric oxide synthase gene G894T polymorphism and myocardial infarction: a meta-Analysis of 34 studies involving 21, 068 subjects. PLoS One 2014; 9: e87196.
40. Fogli S, Nieri P, Breschi MC. The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J 2004; 18: 664-675.
41. Dazert P, Meissner K, Vogelgesang S, Heydrich B, Eckel L, Bohm M et al. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am J Pathol 2003; 163: 1567-1577.
42. Jedlitschky G, Burchell B, Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275: 30069-30074.
43. Carvajal JA, Germain AM, Huidobro-Toro JP, Weiner CP. Molecular mechanism of cGMP-mediated smooth muscle relaxation. J Cell Physiol 2000; 184: 409-420.
44. Flesch M, Kilter H, Cremers B, Lenz O, Sudkamp M, Kuhn-Regnier F et al. Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. J Pharmacol Exp Ther 1997; 281: 1340-1349.
45. Wollert KC, Fiedler B, Gambaryan S, Smolenski A, Heineke J, Butt E et al. Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension 2002; 39: 87-92.
46. Wang Z, Wang J, Chong SS, Lee CGL. Mining potential functionally significant polymorphisms at the ATP-binding-cassette transporter genes. Curr Pharmacogenomics Personal Med 2009; 7: 40-58.
47. Di Leo A, Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI et al. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-Analysis of individual patient data. Lancet Oncol 2011; 12: 1134-1142.
48. Khiati S, Dalla Rosa I, Sourbier C, Ma X, Rao VA, Neckers LM et al. Mitochondrial topoisomerase I (Top1mt) is a novel limiting factor of doxorubicin cardiotoxicity. Clin Cancer Res 2014; 20: 4873-4881.